Literature DB >> 12680479

Over-the-counter drugs for acute migraine attacks: literature review and recommendations.

Richard G Wenzel1, Carrie A Sarvis, Michelle L Krause.   

Abstract

Migraines affect 28 million people in the United States, and most of these individuals experience attack-related morbidity. Six of every 10 patients with migraine treat their headache exclusively with over-the-counter (OTC) products. Overreliance on OTC agents contributes to preventable morbidity and drug-induced headaches. To evaluate the role of OTC drugs in the management of migraine headaches, we performed a qualitative systematic literature search by using MEDLINE (January 1966-April 2002), analyzed the references of articles returned by the MEDLINE search, and reviewed other pertinent literature. In the studied populations, acetaminophen, aspirin, ibuprofen, and an aspirin-acetaminophen-caffeine combination product were shown to be more effective than placebo at reducing moderate or severe migraine pain to mild or no pain by 2 hours after administration. However, published trials of OTC agents have systematically excluded patients enduring morbidity with 50% or more of attacks and/or vomiting with 20% or more of attacks. Patients who experience disability during the predominance of their attacks are poor candidates for OTC-exclusive therapy and should seek a physician's help for migraine-specific prescription drugs. For those with migraine who encounter disability with less than 50% of attacks and/or vomiting with less than 20% of attacks, sole treatment with OTC products is a feasible option. Patients who fail to obtain acceptable relief after an adequate trial of OTC agents also should be referred to a physician. Pharmacists are well positioned to assess whether patients could benefit from OTC agents or should seek a physician's assistance.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12680479     DOI: 10.1592/phco.23.4.494.32124

Source DB:  PubMed          Journal:  Pharmacotherapy        ISSN: 0277-0008            Impact factor:   4.705


  12 in total

Review 1.  Practical considerations for the treatment of elderly patients with migraine.

Authors:  Paola Sarchielli; Maria Luisa Mancini; Paolo Calabresi
Journal:  Drugs Aging       Date:  2006       Impact factor: 3.923

Review 2.  The pharmacotherapy of chronic pain: a review.

Authors:  Mary E Lynch; C Peter N Watson
Journal:  Pain Res Manag       Date:  2006       Impact factor: 3.037

3.  Didactic migraine education in US doctor of pharmacy programs.

Authors:  Richard G Wenzel; Rosalyn S Padiyara; Jon C Schommer
Journal:  Am J Pharm Educ       Date:  2010-02-10       Impact factor: 2.047

Review 4.  Paracetamol (acetaminophen) with or without an antiemetic for acute migraine headaches in adults.

Authors:  Sheena Derry; R Andrew Moore; Henry J McQuay
Journal:  Cochrane Database Syst Rev       Date:  2010-11-10

Review 5.  Migraine pain, meningeal inflammation, and mast cells.

Authors:  Dan Levy
Journal:  Curr Pain Headache Rep       Date:  2009-06

6.  The pharmacological management of migraine, part 1: overview and abortive therapy.

Authors:  George Demaagd
Journal:  P T       Date:  2008-07

Review 7.  Paracetamol (acetaminophen) with or without an antiemetic for acute migraine headaches in adults.

Authors:  Sheena Derry; R Andrew Moore
Journal:  Cochrane Database Syst Rev       Date:  2013-04-30

8.  CADASIL: Migraine, Encephalopathy, Stroke and Their Inter-Relationships.

Authors:  Rhea Yan Ying Tan; Hugh Stephen Markus
Journal:  PLoS One       Date:  2016-06-16       Impact factor: 3.240

9.  Popularity and customer preferences for over-the-counter Chinese medicines perceived by community pharmacists in Shanghai and Guangzhou: a questionnaire survey study.

Authors:  Shuai Ge; Tian-Tian He; Hao Hu
Journal:  Chin Med       Date:  2014-09-13       Impact factor: 5.455

10.  Chlorpheniramine Potentiates the Analgesic Effect in Migraine of Usual Caffeine, Acetaminophen, and Acetylsalicylic Acid Combination.

Authors:  Victor A Voicu; Ion Mircioiu; Roxana Sandulovici; Constantin Mircioiu; Cristina Plesa; Bruno S Velescu; Valentina Anuta
Journal:  Front Pharmacol       Date:  2017-10-24       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.